vimarsana.com

Page 33 - பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா பெரல்மேன் பள்ளி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A

Date Time CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.

Penn study suggests those who had COVID-19 may only need one vaccine dose

Penn study suggests those who had COVID-19 may only need one vaccine dose
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Protein Found to Control Drivers of Normal Growth and Cancer

Protein Found to Control Drivers of Normal Growth and Cancer News provided by Share this article Share this article NEW YORK, April 14, 2021 /PRNewswire/ Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled. Publishing online in Nature on April 14, the new study revolves around the ability of each human cell to divide in two, with this process repeating itself until a single cell (the fertilized egg) becomes a body with trillions of cells. For each division, a cell must follow certain steps, most of which are promoted by proteins called cyclins.

Sanford Health $1M award given to Dr Carl June for cancer-killing therapy

Sanford Health $1M award given to Dr. Carl June for cancer-killing therapy Sanford Health gave its $1 million 2021 Sanford Lorraine Cross Award to Dr. Carl June, the health system announced Tuesday, April 13. June and colleagues who developed a therapy that finds and kills leukemia cancer cells.  11:54 am, Apr. 14, 2021 × Sanford Health President and CEO Bill Gassen, center, presents Dr. Carl June with the $1 million Sanford Lorraine Award for June s development of a therapy that kills leukemia cancer cells, as Executive Vice President Micah Aberson looks on, Tuesday, April 13, 2021. Submitted/ Sanford Health SIOUX FALLS, S.D. Sanford Health has awarded a $1 million award for medical breakthroughs to a cancer and immune system researcher who developed a therapy that finds and kills leukemia cancer cells.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.